These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 32985934)

  • 21. A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma.
    Terui Y; Rai S; Izutsu K; Yamaguchi M; Takizawa J; Kuroda J; Ishikawa T; Kato K; Suehiro Y; Fukuhara N; Ohmine K; Goto H; Yamamoto K; Kanemura N; Ueda Y; Ishizawa K; Kumagai K; Kawasaki A; Saito T; Hashizume M; Shibayama H
    Cancer Sci; 2021 Jul; 112(7):2845-2854. PubMed ID: 33942442
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.
    Tilly H; Morschhauser F; Sehn LH; Friedberg JW; Trněný M; Sharman JP; Herbaux C; Burke JM; Matasar M; Rai S; Izutsu K; Mehta-Shah N; Oberic L; Chauchet A; Jurczak W; Song Y; Greil R; Mykhalska L; Bergua-Burgués JM; Cheung MC; Pinto A; Shin HJ; Hapgood G; Munhoz E; Abrisqueta P; Gau JP; Hirata J; Jiang Y; Yan M; Lee C; Flowers CR; Salles G
    N Engl J Med; 2022 Jan; 386(4):351-363. PubMed ID: 34904799
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent Advances in Antibody Drug Conjugates for Lymphoma.
    Russler-Germain DA; Kahl BS
    Oncology (Williston Park); 2020 Dec; 34(12):522-534. PubMed ID: 33395492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomas.
    Dimou M; Papageorgiou SG; Stavroyianni N; Katodritou E; Tsirogianni M; Kalpadakis C; Banti A; Arapaki M; Iliakis T; Bouzani M; Verrou E; Spanoudakis E; Giannouli S; Marinakis T; Mandala E; Mparmparousi D; Sachanas S; Dalekou-Tsolakou M; Hatzimichael E; Vadikolia C; Violaki V; Poziopoulos C; Tsirkinidis P; Chatzileontiadou S; Vervessou E; Ximeri M; Sioni A; Konstantinidou P; Kyrtsonis MC; Siakantaris MP; Angelopoulou MK; Pappa V; Konstantopoulos K; Panayiotidis P; Vassilakopoulos TP
    Hematol Oncol; 2021 Aug; 39(3):336-348. PubMed ID: 33583077
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma.
    Yu B; Liu D
    J Hematol Oncol; 2019 Sep; 12(1):94. PubMed ID: 31500657
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Loncastuximab tesirine for treatment of relapsed or refractory diffuse large B cell lymphoma.
    Goparaju K; Caimi PF
    Expert Opin Biol Ther; 2021 Nov; 21(11):1373-1381. PubMed ID: 34505550
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes of polatuzumab vedotin-containing regimens in real-world setting of relapsed and or refractory diffuse large B-cell lymphoma patients: a matched-control analysis from the Thai Lymphoma Study Group (TLSG).
    Rattanathammethee T; Norasetthada L; Bunworasate U; Wudhikarn K; Julamanee J; Noiperm P; Lanamtieng T; Phiphitaporn P; Navinpipat M; Kanya P; Jit-Ueakul D; Wongkhantee S; Suwannathen T; Chaloemwong J; Wong P; Makruasi N; Khuhapinant A; Prayongratana K; Niparuck P; Kanitsap N; Suwanban T; Intragumtornchai T
    Ann Hematol; 2023 Jul; 102(7):1887-1895. PubMed ID: 37202499
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evolving Landscape of Antibody Drug Conjugates in Lymphoma.
    Prakash R; Subbiah V; Iyer SP
    Cancer J; 2022 Nov-Dec 01; 28(6):479-487. PubMed ID: 36383911
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population pharmacokinetics and exposure-response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study.
    Deng R; Gibiansky L; Lu T; Flowers CR; Sehn LH; Liu Q; Agarwal P; Liao MZ; Dere R; Lee C; Man G; Hirata J; Li C; Miles D
    CPT Pharmacometrics Syst Pharmacol; 2024 Jun; 13(6):1055-1066. PubMed ID: 38622879
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An Anti-CD22-
    Yu SF; Lee DW; Zheng B; Del Rosario G; Leipold D; Booler H; Zhong F; Carrasco-Triguero M; Hong K; Yan P; Rowntree RK; Schutten MM; Pillow T; Sadowsky JD; Dragovich PS; Polson AG
    Mol Cancer Ther; 2021 Feb; 20(2):340-346. PubMed ID: 33273056
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress.
    Chu Y; Zhou X; Wang X
    J Hematol Oncol; 2021 Jun; 14(1):88. PubMed ID: 34090506
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Investigational Antibody-Drug Conjugates for Treatment of B-lineage Malignancies.
    Herrera AF; Molina A
    Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):452-468.e4. PubMed ID: 29804872
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polatuzumab Vedotin for Relapsed/Refractory Aggressive B-cell Lymphoma: A Multicenter Post-marketing Analysis.
    Smith SD; Lopedote P; Samara Y; Mei M; Herrera AF; Winter AM; Hill BT; Shadman M; Ujjani C; Lynch RC; Jacobson CA; Kim AI; Caimi P; Milano F; Gopal AK
    Clin Lymphoma Myeloma Leuk; 2021 Mar; 21(3):170-175. PubMed ID: 33431309
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS).
    Morschhauser F; Flinn IW; Advani R; Sehn LH; Diefenbach C; Kolibaba K; Press OW; Salles G; Tilly H; Chen AI; Assouline S; Cheson BD; Dreyling M; Hagenbeek A; Zinzani PL; Jones S; Cheng J; Lu D; Penuel E; Hirata J; Wenger M; Chu YW; Sharman J
    Lancet Haematol; 2019 May; 6(5):e254-e265. PubMed ID: 30935953
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emerging antibody-drug conjugates for treating lymphoid malignancies.
    Wolska-Washer A; Robak P; Smolewski P; Robak T
    Expert Opin Emerg Drugs; 2017 Sep; 22(3):259-273. PubMed ID: 28792782
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preclinical Characterization of the Distribution, Catabolism, and Elimination of a Polatuzumab Vedotin-Piiq (POLIVY
    Yip V; Lee MV; Saad OM; Ma S; Khojasteh SC; Shen BQ
    J Clin Med; 2021 Mar; 10(6):. PubMed ID: 33806916
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience.
    Segman Y; Ribakovsky E; Avigdor A; Goldhecht Y; Vainstein V; Goldschmidt N; Harlev S; Horwitz N; Gutwein O; Gurion R; Itchaki G; Abadi U; Nemets A; Sofer O; Zektser M; Tadmor T; Dally N; Filanovsky K; Leiba M; Sarid N; Benyamini N; Herishanu Y; Ram R; Perry C; Avivi I
    Leuk Lymphoma; 2021 Jan; 62(1):118-124. PubMed ID: 32981410
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Polatuzumab vedotin combined with bendamustine and rituximab for relapsed/refractory diffuse large B-cell lymphoma: A systematic review protocol.
    Eslami M; Mehrabi M; Payandeh M; Saba F
    PLoS One; 2024; 19(8):e0308247. PubMed ID: 39088571
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and pharmacokinetics of polatuzumab vedotin in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma: a phase 1 dose-escalation study.
    Kinoshita T; Hatake K; Yamamoto K; Higuchi Y; Murakami S; Terui Y; Yokoyama M; Maruyama D; Makita S; Hida Y; Saito T; Tobinai K
    Jpn J Clin Oncol; 2021 Jan; 51(1):70-77. PubMed ID: 33029633
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.
    Advani RH; Lebovic D; Chen A; Brunvand M; Goy A; Chang JE; Hochberg E; Yalamanchili S; Kahn R; Lu D; Agarwal P; Dere RC; Hsieh HJ; Jones S; Chu YW; Cheson BD
    Clin Cancer Res; 2017 Mar; 23(5):1167-1176. PubMed ID: 27601593
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.